Azenta Narrows Focus to Life Sciences After $2.9B Semiconductor Exit

TL;DR

**AZTA is all-in on life sciences, ditching legacy businesses to chase high-growth biotech, making it a focused play on critical drug development infrastructure.**

AI Summary

Azenta, Inc. (AZTA) reported a strategic shift to solely focus on life sciences, divesting its semiconductor business in February 2022 for $2.9 billion and classifying its B Medical Systems business as held for sale in Q1 fiscal year 2025. The company now operates in two segments: Sample Management Solutions and Multiomics. Sample Management Solutions offers end-to-end services including Sample Repository Services and Core Products like Automated Stores and Cryogenic Systems. The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and synthesis. Azenta employs approximately 3,000 full-time employees, part-time employees, and contingent workers worldwide as of September 30, 2025, serving approximately 14,000 customers globally across 95 countries. The aggregate market value of non-affiliate common stock was approximately $1,003,383,280 as of March 31, 2025, based on a closing price of $34.64 per share.

Why It Matters

Azenta's complete pivot to life sciences, marked by the $2.9 billion semiconductor divestiture and planned B Medical Systems sale, signals a clear strategic direction for investors. This focus allows for concentrated R&D and market penetration in the high-growth biologics and personalized medicine sectors, potentially enhancing competitive positioning against specialized life science tool providers. For employees, this means a clearer mission and potential for growth within a focused industry. Customers benefit from a dedicated partner in sample management and genomics, crucial for accelerating drug discovery and therapy development, ultimately impacting the broader healthcare market.

Risk Assessment

Risk Level: medium — The company faces medium risk due to its reliance on the highly competitive and rapidly evolving life sciences market, as highlighted in Item 1A, 'Risk Factors.' While the divestiture of the semiconductor business for $2.9 billion provides capital, the ongoing sale of the B Medical Systems business indicates a period of portfolio restructuring, which can introduce operational complexities and potential revenue fluctuations.

Analyst Insight

Investors should monitor Azenta's execution on its streamlined life sciences strategy, particularly its ability to drive revenue growth and profitability in the Sample Management Solutions and Multiomics segments. Evaluate future earnings reports for progress on integrating acquisitions and expanding its customer base beyond the current 14,000 global customers.

Key Numbers

• $2.9B — Semiconductor Business Divestiture (Cash proceeds from the sale in February 2022, enabling focus on life sciences.)
• $1.003B — Market Value of Non-Affiliate Common Stock (As of March 31, 2025, reflecting investor valuation.)
• 3,000 — Total Employees (Workforce size as of September 30, 2025, supporting global operations.)
• 14,000 — Global Customers (Customer base served across pharmaceutical, biotech, and research institutions.)
• 95 — Countries with Sales (Geographic reach of Azenta's life sciences solutions.)
• $34.64 — Closing Price Per Share (On March 31, 2025, used for market value calculation.)
• 45,989,285 — Shares Outstanding (As of December 1, 2025, indicating current share count.)

Key Players & Entities

• Azenta, Inc. (company) — Registrant
• Nasdaq Stock Market LLC (regulator) — Exchange for common stock
• B Medical Systems (company) — Business classified as held for sale
• $2.9 billion (dollar_amount) — Proceeds from semiconductor business divestiture
• September 30, 2025 (date) — Fiscal year end
• March 31, 2025 (date) — Date for market value calculation
• $1,003,383,280 (dollar_amount) — Aggregate market value of non-affiliate common stock
• 3,000 (number) — Approximate number of employees
• 14,000 (number) — Approximate number of global customers
• 95 (number) — Number of countries with sales

FAQ

Risk Factors

• Dependence on Key Customers [high — market]: Azenta's revenue is significantly dependent on a limited number of large customers, particularly in the Sample Management Solutions segment. The loss of any of these key customers, or a substantial reduction in their purchases, could have a material adverse effect on the company's financial condition and results of operations. For example, the loss of a single major customer could impact revenue significantly.
• Supply Chain Disruptions [medium — operational]: The company relies on a global supply chain for its products and components. Disruptions in this supply chain, whether due to geopolitical events, natural disasters, or supplier issues, could impact the company's ability to manufacture and deliver products on time, leading to lost sales and increased costs. This was a concern highlighted in recent years across many industries.
• Compliance with Life Sciences Regulations [medium — regulatory]: Operating in the life sciences industry requires strict adherence to various regulatory standards, including those related to data privacy (e.g., HIPAA), product quality, and environmental impact. Failure to comply with these regulations could result in fines, penalties, and reputational damage, impacting the company's ability to operate and serve its customers.
• Intense Competition [medium — market]: The life sciences market is highly competitive, with numerous established players and emerging companies. Azenta faces competition from companies offering similar sample management, automation, and genomic services. This competitive pressure could affect pricing, market share, and the ability to innovate and grow.
• Integration of Acquisitions [medium — operational]: Azenta has a history of growth through acquisitions. The successful integration of acquired businesses is critical for realizing the intended benefits and synergies. Any difficulties in integrating new companies, technologies, or cultures could disrupt operations and negatively impact financial performance.
• Foreign Currency Exchange Rate Fluctuations [low — financial]: With operations and sales in approximately 95 countries, Azenta is exposed to fluctuations in foreign currency exchange rates. Adverse movements in these rates could negatively impact the reported value of international revenues and expenses, as well as the company's financial position.
• Cybersecurity Threats [medium — operational]: As a technology and data-reliant company, Azenta is vulnerable to cybersecurity threats, including data breaches and system disruptions. Such incidents could compromise sensitive customer data, disrupt operations, and lead to significant financial and reputational damage. The company has implemented measures to address these risks.

Industry Context

Azenta operates within the highly dynamic and growing life sciences industry, which is driven by advancements in biotechnology, pharmaceuticals, and research. The competitive landscape includes established players and innovative startups offering specialized solutions for sample management, automation, and genomic analysis. Key trends include the increasing volume and complexity of biological samples, the need for advanced data analytics, and the demand for integrated solutions across the R&D pipeline.

Regulatory Implications

Azenta's focus on life sciences subjects it to stringent regulatory oversight, particularly concerning data privacy (e.g., HIPAA), product safety, and quality control in pharmaceutical and biotech applications. Compliance with these evolving regulations is critical to avoid penalties and maintain customer trust. The company must also navigate international regulations across the 95 countries it serves.

What Investors Should Do

1. Monitor the performance of the Sample Management Solutions and Multiomics segments closely.
2. Evaluate the success of integrating past and potential future acquisitions.
3. Assess the impact of competition and pricing pressures within the life sciences market.
4. Track the company's progress in simplifying its portfolio, specifically the sale of B Medical Systems.

Key Dates

• 2022-02-01: Divestiture of Semiconductor Business — Azenta received $2.9 billion in cash, enabling a strategic shift to focus solely on the life sciences industry.
• 2021-12-01: Corporate Name Change to Azenta, Inc. — Reflects the company's strategic pivot and focus on life sciences, trading under the symbol AZTA.
• 2025-01-01: Announcement of B Medical Systems Sale Pursuit — Classified as held for sale, this move aims to simplify the portfolio and focus on core Sample Management Solutions and Multiomics segments.

Glossary

Discontinued Operations

Financial reporting treatment for a component of a business that has been sold or is classified as held for sale, where its results are reported separately from continuing operations. (Applies to Azenta's semiconductor business divestiture and its B Medical Systems business, allowing investors to assess the performance of the core life sciences operations.)

Sample Management Solutions

Azenta's segment offering end-to-end services for biological and chemical samples, including automated storage systems and repository services. (Represents a core business segment for Azenta, focused on supporting the life sciences industry's needs for sample integrity and accessibility.)

Multiomics

Azenta's segment providing genomic and other sample analysis services, such as gene sequencing and synthesis. (Another key segment for Azenta, contributing to its comprehensive offering in life sciences research and development.)

GAAP

Generally Accepted Accounting Principles, the common set of accounting standards and procedures used in the United States. (Governs how Azenta reports its financial information, including the classification of its B Medical Systems business as held for sale.)

Year-Over-Year Comparison

The company has undergone a significant transformation, divesting its semiconductor business in February 2022 for $2.9 billion to focus exclusively on life sciences. This strategic shift means that year-over-year comparisons will primarily reflect the performance of the Sample Management Solutions and Multiomics segments, excluding the historical contributions of the divested semiconductor operations. Investors should look for growth and margin improvements within these core life sciences businesses, as well as the successful execution of the B Medical Systems divestiture, which is now classified as held for sale.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value AZTA The Nasdaq Stock Mar
• $34.64 — based on the closing price per share of $34.64 on March 31, 2025 on the Nasdaq Stock M
• $0 — hares of the registrant's Common Stock, $0.01, par value, were outstanding. DOCUM
• $2.9 billion — nductor businesses in February 2022 for $2.9 billion in cash and since then operate solely a

Filing Documents

• azta20250930_10k.htm (10-K) — 5044KB
• ex_885808.htm (EX-10.12) — 36KB
• ex_852662.htm (EX-19) — 72KB
• ex_852663.htm (EX-21.01) — 14KB
• ex_852664.htm (EX-23.01) — 2KB
• ex_852665.htm (EX-31.01) — 9KB
• ex_852666.htm (EX-31.02) — 9KB
• ex_852667.htm (EX-32) — 8KB
• azlogo.jpg (GRAPHIC) — 14KB
• perfgraph.jpg (GRAPHIC) — 66KB
• 0001437749-25-036931.txt ( ) — 26365KB
• azta-20250930.xsd (EX-101.SCH) — 114KB
• azta-20250930_cal.xml (EX-101.CAL) — 135KB
• azta-20250930_def.xml (EX-101.DEF) — 869KB
• azta-20250930_lab.xml (EX-101.LAB) — 712KB
• azta-20250930_pre.xml (EX-101.PRE) — 944KB
• azta20250930_10k_htm.xml (XML) — 7258KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 10 Item 1B. Unresolved Staff Comments 20 Item 1C. Cybersecurity 21 Item 2.

Properties

Properties 22 Item 3.

Legal Proceedings

Legal Proceedings 22 Item 4. Mine Safety Disclosures 22 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 23 Item 6. [Reserved] 24 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 40 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 93 Item 9A.

Controls and Procedures

Controls and Procedures 93 Item 9B. Other Information 96 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 96 PART III Item 10. Directors, Executive Officers and Corporate Governance 96 Item 11.

Executive Compensation

Executive Compensation 96 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 96 Item 13. Certain Relationships and Related Transactions, and Director Independence 96 Item 14. Principal Accountant Fees and Services 96 PART IV Item 15. Exhibits and Financial Statement Schedules 97 Item 16. Form 10-K Summary 99

SIGNATURES

SIGNATURES 100 2 Table of Contents INFORMATION RELATED TO FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements may be identified by words such as "expect," "estimate," "intend," "believe," "anticipate," "may," "will," "should," "could," "continue," "likely," or similar terms or variations. Examples of forward-looking statements include, but are not limited to, statements regarding our future revenue, margins, costs, operating expenses, tax expenses, capital expenditures, earnings, profitability, product development, demand, acceptance and market share, competitiveness, market opportunities and performance, levels of research and development, the success of our marketing, sales and service efforts, outsourced activities, anticipated manufacturing, customer and technical requirements, the ongoing viability of the solutions that we offer and our customers' success, our management's plans and objectives for our current and future operations and business focus, litigation, our ability to retain, hire and integrate skilled personnel, our ability to identify and address increased cybersecurity risks, the anticipated growth prospects of our business, the expected benefits and other statements relating to our divestitures and acquisitions (including timing), the adequacy, effectiveness and success of cost saving plans and our business transformation initiatives, our ability to continue to identify acquisition targets and successfully acquire and integrate desirable products and services and realize expected revenues and revenue synergies, our adoption of newly issued accounting guidance, the levels of customer spending, our dependence on key suppli

Business

Item 1. Business Overview We are a leading global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. We entered the life sciences market in 2011, leveraging our in-house precision automation and cryogenics capabilities that we were then applying in the semiconductor manufacturing market. This led us to develop and provide solutions for automated ultra-cold storage. Since then, we have expanded our life sciences offerings through internal investments and through a series of acquisitions. We support our customers from research and clinical development to commercialization with our sample management and automated storage systems, as well as genomic services expertise to help our customers bring impactful therapies to market faster. We understand the importance of sample integrity and offer a broad portfolio of products and services supporting customers at every stage of the life cycle of samples, including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software, along with sample repository services. Our expertise, global footprint, and leadership positions enable us to be a trusted global partner to pharmaceutical, biotechnology and life sciences research institutions. In total, we employ approximately 3,000 full-time employees, part-time employees and contingent workers worldwide as of September 30, 2025 and have sales in approximately 95 countries. We are headquartered in Burlington, Massachusetts and have operations in North America, Asia and Europe. Our Company was founded in 1978 and became a leading automation provider and partner to the global semiconductor manufacturing industry. We divested the last of our semiconductor businesses in February 2022 for $2.9 billion in cash and since then operate solely as a life sciences company. On December 1, 2021, we changed our corporate name from "Brooks Automation, Inc." to "Aze

View Full Filing

View this 10-K filing on SEC EDGAR